VRNA - ベロナ・ファ―マ （Verona Pharma plc）

David Zaccardelli , President And CEO at Verona Pharma (NASDAQ: VRNA ), made a large insider sell on November 2, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Tuesday showed that Zaccardelli sold 506,904 shares of Verona Pharma at a price of $0.64. The total transaction amounted to $324,476. Following the transaction, Zaccardelli still owns 16,845,352 shares of Verona Pharma worth $87,932,737. Verona Pharma shares are trading up 2.15% at $5.22 at the time of this writing on Thursday morning. Now trade stocks online commission free with Full story available on Benzinga.com

LONDON and RALEIGH, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., President and Chief Executive Officer, will present at the following investor conferences in November 2021:

Asthma is a lung disease that affects millions of people worldwide. Breathing problems, chest pain, coughing, and wheezing are also possible symptoms. The global asthma and COPD market is expected to account around US$ 30,710.2 Mn in terms of value in

LONDON and RALEIGH, N.C., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the three and nine months ended September 30, 2021 on Tuesday, November 9, 2021 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.

LONDON and RALEIGH, N.C., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ: VRNA ) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the presentation of Phase 2 data demonstrating the positive effect of a pressurized metered-dose inhaler ("pMDI") formulation of ensifentrine in patients with moderate to severe chronic obstructive pulmonary disease ("COPD") at CHEST Annual Meeting ("CHEST") 2021 taking place on October 17-20. The data are published in the CHEST Annual Meeting on-line supplement. Data from Part B of the two-part study, first reported on February 2, 2021 , showed ensifentrine delivered by pMDI over one week provided statistically significant, clinically meaningful and dose-dependent improvements in lung function and was well tolerated with an adverse advent profile similar to placebo. The data are consistent with results for dry powder inhaler ("DPI") and nebulizer formulations of ensifentrine. Ensifentrine is an investigational, first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 ("PDE3" and "PDE4").

Verona Pharma plc NOTICE & PROXY STATEMENT Annual General Meeting of Shareholders April 27, 2021 1:00 p.m. … | March 21, 2021

LONDON and RALEIGH, N.C., March 01, 2021 -- Verona Pharma plc , a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive… | March 1, 2021

Verona Pharma announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…

LONDON and RALEIGH, N.C., Feb. 18, 2021 (GLOBE NEWSWIRE) — Verona Pharma plc (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the fourth quarter and full year ended December 31, 2020 on Thursday, February 25, 2021 and host an investment community conference call… Read More »Verona Pharma to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update

Zosano Pharma (NASDAQ:ZSAN) and Verona Pharma (NASDAQ:VRNA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership. Valuation & Earnings This table compares Zosano Pharma and Verona Pharma’s top-line revenue, earnings per […]